LEADER

Liraglutide and cardiovascular outcomes in type 2 diabetes - The New England Journal of Medicine - 2016

Brief Summary:

Among patients with T2DM at increased risk for CVD, liraglutide was associated with a reduction in CV events when compared to placebo.

Reference: http://www.ncbi.nlm.nih.gov/pubmed/27295427